Fundamental analysis · SEC EDGAR · TTM through 31/03/2026
TEVA · NYSE · Healthcare
Fundamental quality
52
out of 100
Source: SEC EDGAR · TTM through 31/03/2026
The score combines growth, profitability and financial strength. Here its profitability weighs in its favor, while its financial strength drags it down the most.
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2021 | 15,878 | 417 | 236 | -762 |
| 2022 | 14,925 | -2,446 | 1,042 | -715 |
| 2023 | 15,846 | -559 | 842 | -1,577 |
| 2024 | 16,544 | -1,639 | 749 | -1,542 |
| 2025 | 17,258 | 1,410 | 1,148 | -1,758 |
Between 2021 and 2025, revenue went from $15,878M to $17,258M (+9%) and net income went from $417M to $1,410M (+238%).
Annual figures in millions of U.S. dollars ($M) per SEC filings. Net debt is total debt minus cash.
Is Teva Pharmaceutical Industries Ltd a profitable company?
Teva Pharmaceutical Industries Ltd is profitable, with a net margin of 9%, though a thin one.
Does Teva Pharmaceutical Industries Ltd have a lot of debt?
Yes, its leverage is high: net debt is 8.42 times its EBITDA.
Is Teva Pharmaceutical Industries Ltd growing?
Its revenue has grown 4.7% annualized in recent years.
Does Teva Pharmaceutical Industries Ltd generate cash?
Yes. It converts about 6.8% of its revenue into free cash flow.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
Is Teva Pharmaceutical Industries Ltd cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Brokers you can use to invest in U.S. and European stocks.
The serious investor's standard →
Popular in the U.S. →
Other analyses
NVIDIA (NVDA) · Microsoft (MSFT) · Apple (AAPL) · Alphabet (Google) (GOOGL) · Amazon (AMZN) · Meta Platforms (META) · see more →